Zacks Investment Research
Sat, May 23rd, 2026
Most Recent Stories
Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing protein therapeutics that modulate transforming growth factor-beta family signaling across skeletal muscle, bone, and adipose...
Keros Therapeutics KROS posted a messy first-quarter 2026 print, with a wider-than-expected loss and a steep revenue decline. The headline numbers look worse than the underlying operating reality because...
Keros Therapeutics KROS is recasting itself as a neuromuscular execution story, anchored by rinvatercept (KER-065) and a catalyst path that begins in 2026. The shift comes as the company leans into selective...
Brian Bolan is the aggressive growth stock strategist at Zacks Investment Research and his big idea this week is that there is more to space than just SpaceX. Over the last year there's been several...
BP plc BP and Enterprise Products Partners LP EPD are two major players in the energy industry with contrasting business operations. BP is an integrated energy company with operations spanning production,...
Enterprise Products Partners LP’s EPD pipeline network spans more than 50,000 miles, transporting oil, natural gas and other commodities. The partnership also has more than 300 million barrels of liquid...
Cisco Systems CSCO shares have risen 33.4% in a month, outperforming the broader Zacks Computer & Technology sector’s return of 10.4%. The company has been benefiting from a strong AI push despite stiff...
Sun Communities SUI is narrowing its focus with a major portfolio move. The REIT has agreed to sell its U.K. assets, including Park Holidays, to funds affiliated with Aermont Capital in an all-cash deal...
High oil prices have been making newspaper headlines, as the Iran war shock has pushed commodity prices back toward their glory days. Handsome oil prices are supporting increased crude production, which...
Altimmune ALT, a late clinical-stage biotech, is focused on developing therapies for liver diseases. Its lead pipeline candidate, pemvidutide, is a balanced 1:1 glucagon/GLP-1 dual receptor agonist and...
